Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 746 across all filing types
Latest filing 2015-05-22 Board/Management Inform…
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
FORM 8-K FILING DOCUMENT
Board/Management Information Classification · 100% confidence The document is a Form 8-K filing with the SEC, dated May 18, 2015, reporting the resignation of a board member and the appointment of a new director. It details changes in the company's board of directors and committee memberships. There is no financial data or report content, only management changes. This fits the category of Board/Management Information (MANG). The document length is 4378 characters, which is consistent with a typical 8-K filing for management changes. Therefore, the classification is MANG with high confidence.
2015-05-22 English
10-Q
Interim / Quarterly Report Q1 2015
2015-05-12 English
FORM 8-K FILING DOCUMENT
Earnings Release Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated May 12, 2015, reporting the company's financial results for the quarter ended March 31, 2015. It specifically states that the company announced its financial results via a press release attached as Exhibit 99.1. The document is short (2992 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). The document is not the full quarterly report (IR) but an announcement of results. Therefore, the correct classification is Earnings Release (ER).
2015-05-12 English
Director's Dealing 2015
Director's Dealing
2015-05-06 English
Director's Dealing 2015
Director's Dealing
2015-05-06 English
Director's Dealing 2015
Director's Dealing
2015-05-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.